Final results of a single-arm, open-label, multicenter phase 2 study of the radiopharmaceutical [ <sup>177</sup> Lu]Lu-DOTA-TATE and [ <sup>68</sup> Ga]Ga-DOTA-TATE in adults with advanced intracranial meningioma.
Sylvia C. Kurz(Center for Neuro-Oncology), Timothy Shepherd(NYU Langone Health), Marissa Barbaro(NYU Langone Health), Glen Stevens(Cleveland Clinic), John G. Golfinos(NYU Langone Health), Alejandro Torres-Trejo(Cleveland Clinic), Mina Lobbous(Cleveland Clinic), Mark G. Malkin(Cleveland Clinic), Erik P. Sulman(NYU Langone Health), Alexandra Miller(Memorial Sloan Kettering Cancer Center), Joshua S. Silverman(NYU Langone Health), David Zagzag, Matija Snuderl(NYU Langone Health), Kent P. Friedman(New York University), Andrew Dhawan(Cleveland Clinic), David M. Peereboom(Cleveland Clinic), Andrea Troxel(NYU Langone Health), Christine Cordova(Cleveland Clinic), Douglas Kondziolka(NYU Langone Health), Elçin Zan(Cornell University)
Cited by 0
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth
|Cell|2016|277
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
|Nature Biotechnology|2005|238